NCT02817204

Brief Summary

The purpose of this study is to determine the effect of aerobic exercise training on microcirculation rarefaction in Chinese young male primary hypertensive patients stage 1. Hypertension is one of the most common world-wide chronic diseases, and it is showing a growing younger trend, which with mild blood pressure elevated would not be diagnose in time until blood pressure raises up or symptoms show up (Mild blood pressure indicates blood pressures ranging from 140 to 159 mmHg systolic and/or 90 to 99 mmHg diastolic). However, cumulative evidences prove that microvascular rarefaction exist in hypertensive patients with even primary hypertension stage 1. Exercise prescription is gathering great importance in preventive health. Aerobic exercise, especially, has the potential to diminish blood pressure values, and aerobic exercise can promote angiogenesis in coronary heart disease. Notch signaling plays an important role in vascular formation and maintenance. However, there is no prospective, randomized, controlled, clinic trial to investigate the effect of exercise on microcirculation rarefaction in hypertension. In summary, investigators propose a hypothesis that aerobic exercise might not only have a blood pressure lowing effect but also improve microcirculation rarefaction in Chinese male adults with primary mild hypertension. For that, subjects will be enrolled for one pre-intervention cardiopulmonary exercise test (CPET) and then randomized in aerobic exercise intervention group and control group (only health education), the intervention will be carried out by Cycle Ergometer, the protocol consists of 3 sessions a day: 3 minutes Warm up, 45 minutes Resistance Exercise at 75% of HRmax; 10 minutes Recovery. Thus 58 minutes a day and 5 days a week (about 2000kcal) and 12 weeks in total. Prior and after all intervention sessions (12 weeks), nail fold capillary microscopy and retinal capillary Optical Coherence Tomography(OCT) angiography will be assessed, as well as 24h blood pressure monitoring, echocardiography, forearm blood flow and reactive hyperemia by venous occlusion plethysmography (FMD), PWV, central arterial pressure, RHI with Endopat, also the quantification of endothelial progenistor cells(EPCs) separated from peripheral blood.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started May 2016

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 22, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 29, 2016

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2017

Completed
Last Updated

April 25, 2017

Status Verified

April 1, 2017

Enrollment Period

1.2 years

First QC Date

June 22, 2016

Last Update Submit

April 23, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Retinal capillary density with Quantitative Optical Coherence Tomography(OCT) angiography(OCT))

    Change from Baseline retinal capillary density at 12 weeks

  • Nail fold capillary numbers per square millimeter( /mm²)

    Change from Baseline nail fold capillary density at 12 weeks

Secondary Outcomes (5)

  • 24 hours ambulatory blood pressure (ABP) in millimeters of mercury(mmHg)

    Change from Baseline Systolic Blood Pressure and Diastolic Blood Pressure at 12 weeks

  • Flow-mediated Dilation(FMD) in %

    Change from Baseline percentage at 12 weeks

  • Reactive Hyperemia Index(RHI) in the ratio of the average amplitude of the PAT signal

    Change from Baseline ratio at 12 weeks

  • Abilities of tube formation of endothelial progenistor cells(EPCs) in tube numbers

    Change from Baseline tube numbers at 12 weeks

  • Left Ventricular End-diastolic Volume (LVEDV) in milliliter(ml)

    Change from Baseline volume at 12 weeks

Study Arms (2)

Aerobic Exercise group

EXPERIMENTAL

Cardio Pulmonary Exercise Test(CPET) Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks

Behavioral: Aerobic ExerciseBehavioral: Health Education

Health Education Group

OTHER

Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol Cardio Pulmonary Exercise Test(CPET) No Cycle ergometer exercise

Behavioral: Health Education

Interventions

Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks

Aerobic Exercise group

Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol

Aerobic Exercise groupHealth Education Group

Eligibility Criteria

Age25 Years - 40 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Subjects range from 18 to 40 years old.
  • male
  • Blood pressure is primary hypertension stage I(systolic blood pressure 140 to 159 mmHg and/or diastolic blood pressure 90 to 99 mmHg).
  • Able to participate in exercise
  • No regular physically active in the last 4 months
  • Provide informed consent and willingness to cooperate with the study protocol

You may not qualify if:

  • Less than 18 years old or above 40 years old
  • Secondary hypertension.
  • Females
  • Systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic renal failure, tuberculosis, and autoimmune diseases
  • Medical history of cardiovascular disease: acute myocardial infarct, stable angina, unstable angina, heart failure, atrial fibrillation, atrioventricular blockade, peripheral vascular disease or cerebrovascular accident
  • Patients who are unfavorable of long-term follow-up or poor compliance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Affiliated Hospital,Sun Yat-sen University

Guangzhou, Guangdong, 510000, China

RECRUITING

Related Publications (1)

  • Liang J, Li Y, Chen L, Xia W, Wu G, Tong X, Su C, He J, Lin X, Tao J. Systemic microvascular rarefaction is correlated with dysfunction of late endothelial progenitor cells in mild hypertension: a substudy of EXCAVATION-CHN1. J Transl Med. 2019 Nov 12;17(1):368. doi: 10.1186/s12967-019-2108-8.

MeSH Terms

Conditions

Essential Hypertension

Interventions

Exercise

Condition Hierarchy (Ancestors)

HypertensionVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Haipeng Xiao, PhD

    First Affiliated Hospital, Sun Yat-Sen University

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor,PhD

Study Record Dates

First Submitted

June 22, 2016

First Posted

June 29, 2016

Study Start

May 1, 2016

Primary Completion

July 30, 2017

Study Completion

July 30, 2017

Last Updated

April 25, 2017

Record last verified: 2017-04

Data Sharing

IPD Sharing
Will not share

Locations